Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® ...

Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® ...

Investigational ZORYVE cream 0.05% was formulated for the delicate skin of infants and young children with mild to moderate atopic dermatitisTopline results anticipated in Q1 2026The U.S. FDA approved ZORYVE cream 0.05% for the treatment of mild to moderate atopic…

Safety and Efficacy Evaluation of Roflumilast Cream 0.05% in Infants with Atopic Dermatitis Insights from the INTEGUM...

'Abstract:' Arcutis Biotherapeutics, Inc. has completed enrollment for its Phase 2 clinical trial, INTEGUMENT-INFANT, assessing the safety and efficacy of ZORYVE (roflumilast) cream 0.05% in infants diagnosed with atopic dermatitis (AD). This study is part of Arcutis' broader clinical development program for roflumilast, which has shown promise in other dermatological applications, including psoriasis. Atopic dermatitis is a chronic inflammatory…

Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

Open the article to view the coverage from Arcutis Biotherapeutics